Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has granted Restricted Stock Units (RSUs) representing 4,500 shares of common stock to three new non-executive employees. The RSUs were approved by the company's Compensation Committee as inducement awards under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. These awards fall under the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced its upcoming first quarter 2025 financial results release. The company will disclose its Q1 2025 financial and operating results before the market opens on Tuesday, May 6, 2025.
A conference call to discuss the results is scheduled for 8:30 a.m. Eastern Time on the same day. Interested parties can access the live broadcast in listen-only mode via webcast, with telephone participants encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM) announced that Evernorth Health Services, a Cigna subsidiary, has expanded coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older with major depressive disorder (MDD). This expansion, effective immediately, impacts 15 million covered lives.
The coverage update follows NeuroStar's FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. Several major insurers, including Humana, Aetna, and Medi-Cal, have updated their policies in response to this clearance.
The expansion addresses a significant need, as approximately 4.3 million U.S. adolescents aged 15-21 are affected by major depression. NeuroStar TMS offers a non-drug treatment option that can be used as a first-line add-on therapy with proven clinical outcomes.
Neuronetics (NASDAQ: STIM) has issued updated financial results for Q4 and full year 2024, revising figures initially reported on March 4, 2025. The revisions, related to the Greenbrook TMS acquisition, include:
For Q4 2024: Operating expenses increased to $26.4M from $25.8M, net loss widened to $(12.7M) from $(12.2M), loss per share increased to $(0.34) from $(0.33), and adjusted EBITDA decreased to $(0.4M) from $0.1M.
For Full Year 2024: Operating expenses rose to $88.7M from $88.2M, net loss expanded to $(43.7M) from $(43.2M), loss per share increased to $(1.38) from $(1.37), and adjusted EBITDA declined to $(21.8M) from $(21.3M).
Neuronetics (NASDAQ: STIM) reported its Q4 and full-year 2024 financial results, highlighting significant strategic developments. The company completed the acquisition of Greenbrook TMS on December 9, 2024, and secured $10 million in additional funding from Perceptive Advisors.
Q4 2024 revenue reached $22.5 million, up 11% year-over-year, with U.S. NeuroStar system revenue at $3.8 million and treatment session revenue at $12.9 million. Full-year 2024 revenue was $74.9 million, a 5% increase from 2023.
The company reported a Q4 net loss of $(12.2) million and a full-year net loss of $(43.2) million. In February 2025, Neuronetics completed a secondary offering raising $18.9 million. The company has executed actions to realize over $21 million of the targeted $22 million in annual cost synergies related to the Greenbrook acquisition.
Looking ahead, Neuronetics projects Q1 2025 revenue between $28-30 million and full-year 2025 revenue of $145-155 million. The company expects to achieve cash flow positivity by Q3 2025.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 24,750 shares of common stock to three new non-executive employees. The awards were approved by the company's Compensation Committee in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSU grants have different vesting schedules: three grants will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, while one grant will vest over four years on the second, third, and fourth anniversaries. All grants are contingent upon continued employment with the company through the vesting dates and are subject to the Neuronetics 2020 Inducement Plan terms.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced it will release its fourth quarter 2024 financial and operating results before the market opens on Tuesday, March 4, 2025.
The company will host a conference call to discuss the results at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast in listen-only mode, and telephone participants are encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 15,750 shares of common stock to two new non-executive employees. The awards, approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), serve as material inducements for employment. These RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. The awards are governed by the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM) has priced its previously announced underwritten public offering of 8,000,000 shares of common stock at $2.25 per share, expecting to raise approximately $18 million in gross proceeds before deducting expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,200,000 shares.
The offering is expected to close around February 10, 2025. Canaccord Genuity is acting as sole bookrunner. The net proceeds will be used for general corporate purposes, including sales and marketing, R&D activities, potential acquisitions, inventory purchases, administrative matters, working capital, and capital expenditures.
Neuronetics (NASDAQ: STIM) has announced the launch of an underwritten public offering of its common stock. The company plans to grant the underwriter, Canaccord Genuity , a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. All shares will be offered by the company.
The offering will be conducted under a shelf registration statement previously filed with the SEC on November 9, 2022, and declared effective on November 14, 2022. The final terms, size, and completion of the offering are subject to market conditions and there is no guarantee of completion.